In addition to diagnostics, we offer a range of RGCC-based therapies designed to target cancer at the cellular level:

• Supportive Oligonucleotide Therapy (SOT): SOT is a personalized therapy for cancer, viruses, and pathogens, including Lyme Disease. SOT works by binding to a specific gene in cancer cells or pathogens, disrupting the processes that allow them to survive and grow. This therapy involves analyzing the patient’s blood and creating a complementary oligonucleotide sequence designed to interrupt the survival of these cells.
• Vaxo-Q-Re: This advanced therapy consists of five types of immune cells: macrophages, NK cells, dendritic cells, cytotoxic T lymphocytes, and antibody-producing plasma cells. Originally tested on breast cancer cells, Vaxo-Q-Re is effective across various forms of cancer. It encourages the body’s immune system to target and destroy cancer cells, offering a powerful new tool in cancer treatment.
• Vaccine Prep (ATA): A novel immunotherapy that activates or strengthens specific immune cells to recognize and destroy cancer cells. Vaccine Prep (ATA) uses cellular fragments from dying tumor cells to stimulate the development of dendritic cells, enhancing the body’s natural tumor defense mechanisms.
• Dendritic Cell Therapy: This therapy aims to activate or strengthen the immune system by using dendritic cells to target cancer cells. Dendritic cells can recognize specific antigens on the surface of cancer cells, improving tumor defense while minimizing systemic side effects. This approach is considered highly promising in cancer treatment.